Cyclin-dependent kinases as cellular targets for antiviral drugs

Journal of Antimicrobial Chemotherapy

Volumn 50, Issue 6, 2002, Pages 779-792

  Schang, Luis M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BUTIRINOLACTONE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; FLAVOPIRIDOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYUREA; INDIRUBIN; INDIRUBIN 3' MONOXIME; KENPAULLONE; LACTONE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; OLOMOUCINE; PAULLONE; PURVALANOL; RIBAVIRIN; ROSCOVITINE; STAUROSPORINE; T 276339; UNCLASSIFIED DRUG;

ADENOVIRUS; ANEMIA; ANTIVIRAL ACTIVITY; ASTHENIA; CANCER; CELL DIVISION; CLINICAL TRIAL; CYTOMEGALOVIRUS; DIARRHEA; DOSE RESPONSE; DRUG POTENCY; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; FATIGUE; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; KAPOSI SARCOMA; KIDNEY DISEASE; NONHUMAN; PAPILLOMA VIRUS; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; THROMBOSIS; UTERINE CERVIX CARCINOMA; VARICELLA ZOSTER VIRUS; VIRUS MUTANT; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CYCLIN-DEPENDENT KINASES; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; HUMANS;

EID: 0036924593     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkf227     Document Type: Review

References (145)

1. Crute, J. J., Grygon, C. A., Hargrave, K. D., Simoneau, B., Faucher, A. M., Bolger, G. et al. (2002). Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nature Medicine 8, 386-91.
2. Kleymann, G., Fischer, R., Betz, U. A. K., Hendrix, M., Bender, W., Schneider, U. et al. (2002). New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nature Medicine 8, 392-8.
3. Underwood, M. R., Shewchuk, L. M., Hassell, A. M. & Phelps, W. C. (2000). Searching for antiviral drugs for human papillomaviruses. Antiviral Therapy 5, 229-42.
4. Meijer, L. & Damiens, E. (2002). CDK inhibitors: small molecular weight compounds. In Tumor Suppressing Viruses, Genes and Drugs: Innovative Cancer Therapy Approaches (Maruta, H., Ed.), pp. 145-67. Academic Press, New York, NY, USA.
5. Arris, C. E., Boyle, F. T., Calvert, A. H., Curtin, N. J., Endicott, J. A., Garman, E. F. et al. (2000). Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. Journal of Medicinal Chemistry 43, 2797-804.
6. Kim, K. S., Sack, J. S., Tokarski, J. S., Qian, L., Chao, S. T., Leith, L. et al. (2000). Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects. Journal of Medicinal Chemistry 43, 4126-34.
7. Meijer, L., Borgne, A., Mulner, O., Chong, J. P., Blow, J. J., Inagaki, N. et al. (1997). Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. European Journal of Biochemistry 243, 527-36.
8. Murthi, K. K., Dubay, M., McClure, C., Brizuela, L., Boisclair, M. D., Worland, P. J. et al. (2000). Structure-activity relationship studies of flavopiridol analogues. Bioorganic and Medicinal Chemistry Letters 10, 1037-41.
9. Sausville, E. A., Johnson, J., Alley, M., Zaharevitz, D. & Senderowicz, A. M. (2000). Inhibition of CDKs as a therapeutic modality. Annals of the New York Academy of Sciences 910, 207-22.
10. Senderowicz, A. M., Headlee, D., Stinson, S. F., Lush, R. M., Kalil, N., Villalba, L. et al. (1998). Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. Journal of Clinical Oncology 16, 2986-99.
11. Senderowicz, A. M. (1999). Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Investigational New Drugs 17, 313-20.
12. Senderowicz, A. M. & Sausville, E. A. (2000). Preclinical and clinical development of cyclin-dependent kinase modulators. Journal of the National Cancer Institute 92, 376-87.
13. Stadler, W. M., Vogelzang, N. J., Amato, R., Sosman, J., Taber, D., Liebowitz, D. et al. (2000). Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. Journal of Clinical Oncology 18, 371-5.
14. Vesely, J., Havlicek, L., Strnad, M., Blow, J. J., Donella-Deana, A., Pinna, L. et al. (1994). Inhibition of cyclin-dependent kinases by purine analogues. European Journal of Biochemistry 224, 771-86.
15. Gray, N. S., Wodicka, L., Thunnissen, A. M., Norman, T. C., Kwon, S., Espinoza, F. H. et al. (1998). Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281, 533-8.
16. Legraverend, M., Ludwig, O., Bisagni, E., Leclerc, S., Meijer, L., Giocanti, N. et al. (1999). Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors. Bioorganic and Medicinal Chemistry 7, 1281-93.
17. Wang, D., de la Fuente, C., Deng, L., Wang, L., Zilberman, I., Eadie, C. et al. (2001). Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. Journal of Virology 75, 7266-79.
18. Schang, L. M., Bantly, A., Knockaert, M., Shaheen, F., Meijer, L., Malim, M. H. et al. (2002). Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild type and drug-resistant strains of HSV and HIV-1 by targeting cellular, not viral proteins. Journal of Virology 76, 7874-82.
19. Schulze-Gahmen, U., Brandsen, J., Jones, H. D., Morgan, D. O., Meijer, L., Vesely, J. et al. (1995). Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Proteins 22, 378-91.
20. De Azevedo, W. F., Leclerc, S., Meijer, L., Havlicek, L., Strnad, M. & Kim, S. H. (1997). Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. European Journal of Biochemistry 243, 518-26.
21. Ikuta, M., Kamata, K., Fukasawa, K., Honma, T., Machida, T., Hirai, H. et al. (2001). Crystallographic approach to identification of cyclin-dependent kinase 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 protein. Journal of Biological Chemistry 276, 27548-54.
22. Sausville, E. A., Zaharevitz, D., Gussio, R., Meijer, L., Louarn-Leost, M., Kunick, C. et al. (1999). Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target. Pharmacology and Therapeutics 82, 285-92.
23. Innocenti, F., Stadler, W. M., Iyer, L., Ramirez, J., Vokes, E. E. & Ratain, M. J. (2000). Flavopiridol metabolism in cancer patients is associated with occurrence of diarrhea. Clinical Cancer Research 6, 3400-5.
24. Stinson, S. F., Hill, K., Siford, T. J., Phillips, L. R. & Daw, T. W. (1998). Determination of flavopiridol (L86 8275; NSC 649890) in human plasma by reversed-phase liquid chromatography with electrochemical detection. Cancer Chemotherapy and Pharmacology 42, 261-5.
25. Schwartz, G. K., Ilson, D., Saltz, L., O'Reilly, E., Tong, W., Maslak, P. et al. (2001). Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. Journal of Clinical Oncology 19, 1985-92.
26. Leclerc, S., Gamier, M., Hoessel, R., Marko, D., Bibb, J. A., Snyder, G. L. et al. (2000). Indirubins inhibit glycogen synthase kinase-3beta and CDK5/P25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? Journal of Biological Chemistry 276, 251-60.
27. Oikonomakos, N. G., Schnier, J. B., Zographos, S. E., Skamnaki, V. T., Tsitsanou, K. E. & Johnson, L. N. (2000). Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site. Journal of Biological Chemistry 275, 34566-73.
28. Bible, K. C., Bible, R. H., Jr, Kottke, T. J., Svingen, P. A., Xu, K., Pang, Y. P. et al. (2000). Flavopiridol binds to duplex DNA. Cancer Research 60, 2419-28.
29. Hooijberg, J. H., Broxterman, H. J., Scheffer, G. L., Vrasdonk, C., Heijn, M., de Jong, M. C. et al. (1999). Potent interaction of flavopiridol with MRP1. British Journal of Cancer 81, 269-76.
30. Hooijberg, J. H., Broxterman, H. J., Heijn, M., Fles, D. L., Lankelma, J. & Pinedo, H. M. (1997). Modulation by (iso)flavonoids of the ATPase activity of the multidrug resistance protein. FEBS Letters 413, 344-8.
31. De Azevedo, W. F., Jr, Mueller-Dieckmann, H. J., Schulze-Gahmen, U., Worland, P. J., Sausville, E. & Kim, S. H. (1996). Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proceedings of the National Academy of Sciences, USA 93, 2735-40.
32. Chao, S. H., Fujinaga, K., Marion, J. E., Taube, R., Sausville, E. A., Senderowicz, A. M. et al. (2000). Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. Journal of Biological Chemistry 275, 28345-8.
33. Lam, L., Pickeral, O., Peng, A., Rosenwald, A., Hurt, E., Giltnane, J. et al. (2001). Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biology 2, 0041.1-0041.11.
34. Bresnahan, W. A., Boldogh, I., Chi, P., Thompson, E. A. & Albrecht, T. (1997). Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication. Virology 231, 239-47.
35. Schang, L. M., Phillips, J. & Schaffer, P. A. (11998). Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription. Journal of Virology 72, 5626-37.
36. Schang, L. M., Rosenberg, A. & Schaffer, P. A. (1999). Transcription of herpes simplex virus immediate-early and early genes is inhibited by roscovitine, an inhibitor specific for cellular cyclin-dependent kinases. Journal of Virology 73, 2161-72.
37. Schang, L. M., Rosenberg, A. & Schaffer, P. A. (2000). Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins. Journal of Virology 74, 2107-20.
38. Jordan, R., Schang, L. & Schaffer, P. A. (1999). Transactivation of herpes simplex virus type 1 immediate-early gene expression by virion-associated factors is blocked by an inhibitor of cyclin-dependent protein kinases. Journal of Virology 73, 8843-7.
39. Nelson, P. J., Gelman, I. H. & Klotman, P. E. (2001). Suppression of HIV-1 expression by inhibitors of cyclin-dependent kinases promotes differentiation of infected podocytes. Journal of the American Society of Nephrology 12, 2827-31.
40. Mancebo, H. S., Lee, G., Flygare, J., Tomassini, J., Luu, P., Zhu, Y. et al. (1997). P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes and Development 11, 2633-44.
41. Flores, O., Lee, G., Kessler, J., Miller, M., Schlief, W., Tomassini, J. et al. (1999). Host-cell positive transcription elongation factor b kinase activity is essential and limiting for HIV type 1 replication. Proceedings of the National Academy of Sciences, USA 96, 7208-13.
42. Advani, S. J., Brandimarti, R., Weichselbaum, R. R. & Roizman, B. (2000). The disappearance of cyclins A and B and the increase in activity of the G(2)/M-phase cellular kinase cdc2 in herpes simplex virus 1-infected cells require expression of the alpha22/U(S)1.5 and U(L)13 viral genes. Journal of Virology 74, 8-15.
43. Advani, S. J., Weichselbaum, R. R. & Roizman I, B. (2000). The role of cdc2 in the expression of herpes simplex virus genes. Proceedings of the National Academy of Sciences, USA 97, 10996-1001.
44. Yanagi, K., Talavera, A., Nishimoto, T. & Rush, M. G. (1978). Inhibition of herpes simplex virus type 1 replication in temperature-sensitive cell cycle mutants. Journal of Virology 25, 42-50.
45. Umene, K. & Nishimoto, T. (1996). Inhibition of generation of authentic genomic termini of herpes simplex virus type 1 DNA in temperature-sensitive mutant BHK-21 cells with a mutated CCG1/TAF(II)250gene. Journal of Virology 70, 9008-12.
46. Goto, H., Motomura, S., Wilson, A. C., Freiman, R. N., Nakabeppu, Y., Fukushima, K. et al. (1997). A single-point mutation in HCF causes temperature-sensitive cell-cycle arrest and disrupts VP16 function. Genes and Development 11, 726-37.
47. Hilton, M. J., Mounghane, D., McLean, T., Contractor, N. V., O'Neil, J., Carpenter, K. et al. (1995). Induction by herpes simplex virus of free and heteromeric forms of E2F transcription factor. Virology 213, 624-38.
48. Hossain, A., Holt, T., Ciacci-Zanella, J. & Jones, C. (1997). Analysis of cyclin-dependent kinase activity after herpes simplex virus type 2 infection. Journal of General Virology 78, 3341-8.
49. Kawaguchi, Y., Van Sant, C. & Roizman, B. (1997). Herpes simplex virus 1 alpha regulatory protein ICPO interacts with and stabilizes the cell cycle regulator cyclin D3. Journal of Virology 71, 7328-36.
50. Wilcock, D. & Lane, D. P. (1991). Localization of p53, retinoblastoma and host replication proteins at sites of viral replication in herpes-infected cells. Nature 349, 429-31.
51. Schang, L. M., Bantly, A. & Schaffer, P. A. (2002). Explant-induced reactivation of herpes simplex virus occurs in neurons expressing nuclear cdks2 and 4. Journal of Virology 76, 7724-35.
52. Advani, S. J., Hagglund, R., Weichselbaum, R. R. & Roizman, B. (2001). Posttranslational processing of infected cell proteins 0 and 4 of herpes simplex virus 1 is sequential and reflects the subcellular compartment in which the proteins localize. Journal of Virology 75, 7904-12.
53. Davido, D. & Schaffer, P. (2002). The cyclin-dependent kinase inhibitor roscovitine inhibits the transactivating activity and alters the posttranslational modification of herpes simplex virus type 1 ICPO. Journal of Virology 76, 1077-88.
54. Ehmann, G. L., Burnett, H. A. & Bachenheimer, S. L. (2001). Pocket protein p130/Rb2 is required for efficient herpes simplex virus type 1 gene expression and viral replication. Journal of Virology 75, 7149-60.
55. Jenkins, H. L. & Spencer, C. A. (2001). RNA polymerase II holoenzyme modifications accompany transcription reprogramming in herpes simplex virus type 1-infected cells. Journal of Virology 75, 9872-917.
56. Hayes, T. E., Valtz, N. L. & McKay, R. D. (1991). Downregulation of CDC2 upon terminal differentiation of neurons. New Biologist 3, 259-69.
57. Zhu, Y., Pe'ery, T., Peng, J., Ramanathan, Y., Marshall, N., Marshall, T. et al. (1997). Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes and Development 11, 2622-32.
58. Taylor, S. L. & Moffat, J. F. (2001). V2V replication in vitro is prevented by Roscovitine, an inhibitor of the cell cycle. In Proceedings of the Fourth International Conference on V2V, Abstract A35. The V2V Research Foundation, La Jolla, CA, USA.
59. Ye, M., Duus, K. M., Peng, J., Price, D. H. & Grose, C. (1999). Varicella-zoster virus Fc receptor component gl is phosphorylated on its endodomain by a cyclin-dependent kinase. Journal of Virology 73, 1320-30.
60. Okamoto, H., Cujec, T. P., Peterlin, B. M. & Okamoto, T. (2000). HIV-1 replication is inhibited by a pseudo-substrate peptide that blocks Tat transactivation. Virology 270, 337-44.
61. Pisell, T., Ho, O., Lee, G. & Butera, S. (2001). Spectrum of cdk-9 inhibitory activity against HIV-1 replication among various models of chronic and latent infection. Antiviral Chemistry and Chemotherapy 12, Suppl. 1, 33-41.
62. Rokyta, D., Badgett, M. R., Molineux, I. J. & Bull, J. J. (2002). Experimental genomic evolution: extensive compensation for loss of DNA ligase activity in a virus. Molecular Biology and Evolution 19, 230-8.
63. Arguello, F., Alexander, M., Sterry, J. A., Tudor, G., Smith, E. M., Kalavar, N. T. et al. (1998). Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 91, 2482-90.
64. Drees, M., Dengler, W. A., Roth, T., Labonte, H., Mayo, J., Malspeis, L. et al. (1997). Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clinical Cancer Research 3, 273-9.
65. Patel, V., Senderowicz, A. M., Pinto, D., Jr, Igishi, T., Raffeld, M., Quintanilla-Martinez, L. etal. (1998). Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. Journal of Clinical Investigation 102, 1674-81.
66. Shenfeld, M., Senderowicz, A. M., Sausville, E. A. & Barrent, K. E. (1997). A novel chemotherapeutic agent, flavopiridol, modulates intestinal epithelial chloride secretion. Gastroenterology 112, A404.
67. Keyomarsi, K., Sandoval, L., Band, V. & Pardee, A. B. (1991). Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Research 51, 3602-9.
68. Jakobisiak, M., Bruno, S., Skierski, J. S. & Darzynkiewicz, Z. (1991). Cell cycle-specific effects of lovastatin. Proceedings of the National Academy of Sciences, USA 88, 3628-32.
69. Pippin, J. W., Qu, Q., Meijer, L. & Shankland, S. J. (1997). Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist. Journal of Clinical Investigation 100, 2512-20.
70. Nutley, P. M., Goddard, L. R., Kelland, M., Valenti, L. Brunton D., Eady, G. B. et al. (2000). Antitumour activity and oral bioavailability of the cyclin dependent kinase (CDK) inhibitor roscovitine. Clinical Cancer Research 6, Suppl., 317.
71. Hoessel, R., Leclerc, S., Endicott, J. A., Nobel, M. E., Lawrie, A., Tunnah, P. et al. (1999). Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nature Cell Biology 1, 60-7.
72. Schultz, C., Link, A., Leost, M., Zaharevitz, D. W., Gussio, R., Sausville, E. A. et al. (1999). Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. Journal of Medicinal Chemistry 42, 2909-19.
73. Zaharevitz, D. W., Gussio, R., Leost, M., Senderowicz, A. M., Lahusen, T., Kunick, C. et al. (1999). Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Research 59, 2566-9.
74. Kunick, C., Schultz, C., Lemcke, T., Zaharevitz, D. W., Gussio, R., Jalluri, R. K. et al. (2000). 2-Substituted paullones: CDK1 /cyclin B-inhibiting property and in vitro antiproliferative activity. Bioorganic and Medicinal Chemistry Letters 10, 567-9.
75. Shugar, D. (1999). Viral and host-cell protein kinases: enticing antiviral targets and relevance of nucleoside, and viral thymidine, kinases. Pharmacology and Therapeutics 82, 315-35.
76. Zala, C., Rouleau, D. & Montaner, J. S. (2000). Role of hydroxyurea in treatment of disease due to human immunodeficiency virus infection. Clinical Infectious Diseases 30, S143-50.
77. Gibbs, M. A. & Sorensen, S. J. (2000). Hydroxyurea in the treatment of HIV-1. Annals of Pharmacotherapy 34, 89-93.
78. Tam, R. C., Lau, J. Y. N. & Hong, Z. (2001). Mechanisms of action of ribavirin in antiviral therapies. Antiviral Chemistry and Chemotherapy 12, 261-72.
79. Pleschka, S., Wolff, T., Ehrhardt, C., Hobom, G., Planz, O., Rapp, U. R. et al. (2001). Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade. Nature Cell Biology 3, 301-5.
80. Karpas, A., Lowdell, M., Jacobson, S. K. & Hill, F. (1992). Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK 506. Proceedings of the National Academy of Sciences, USA 89, 8351-5.
81. Rosenwirth, B., Billich, A., Datema, R., Donatsch, P., Hammerschmid, F., Harrison, R. et al (1994). Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a non-immunosuppressive cyclosporine analog. Antimicrobial Agents and Chemotherapy 38, 1763-72.
82. Franke, E. K. & Luban, J. (1996). Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. Virology 222, 279-82.
83. Lori, F., Malykh, A. G., Foli, A., Maserati, R., De Antoni, A., Minoli, L. et al. (1997). Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance. AIDS Research and Human Retroviruses 13, 1403-9.
84. Andrus, L., Szabo, P., Grady, R. W., Hanauske, A. R., Huima-Byron, T., Slowinska, B. et al. (1998). Antiretroviral effects of deoxyhypusyl hydroxylase inhibitors: a hypusine-dependent host cell mechanism for replication of human immunodeficiency virus type 1 (HIV-1). Biochemical Pharmacology 55, 1807-18.
85. Yura, Y., Kusaka, J., Tsujimoto, H., Yoshioka, Y., Yoshida, H. & Sato, M. (1997). Effects of protein tyrosine kinase inhibitors on the replication of herpes simplex virus and the phsophorylation of viral proteins. Intervirology 40, 7-14.
86. Everett, R. D., Orr, A. & Preston, C. M. (1998). A viral activator of gene expression functions via the ubiquitin-proteasome pathway. EMBO Journal 17, 7161-9.
87. Bonjean, K., De Pauw-Gillet, M. C., Defresne, M. P., Colson, P., Houssier, C., Dassonneville, L. et al. (11998). The DNA intercalating alkaloid cryptolepine interferes with topoisomerase 11 and inhibits primarily DNA synthesis in B16 melanoma cells. Biochemistry 37, 5136-46.
88. Kurokawa, M., Hozumi, T., Basnet, P., Nakano, M., Kadota, S., Namba, T. et al. (1998). Purification and characterization of eugeniin as an anti-herpesvirus compound from Geum japonicum and Syzygium aromaticum. Journal of Pharmacology and Experimental Therapeutics 284, 728-35.
89. Moreau, P., Anizon, F., Sancelme, M., Prudhomme, M., Bailly, C., Carrasco, C. et al. (1998). Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle. Journal of Medicinal Chemistry 41, 1631-40.
90. Briggs, C. J., Ott, D. E., Coren, L. V., Oroszlan, S. & Tozser, J. (1999). Comparison of the effect of FK506 and cyclosporin A on virus production in H9 cells chronically and newly infected by HIV-1. Archives of Virology 144, 2151-60.
91. Murata, T., Goshima, F., Koshizuka, T., Takakuwa, H. & Nishiyama, Y. (2001). A single amino acid substitution in the ICP27 protein of herpes simplex virus type 1 is responsible for its resistance to leptomycin B. Journal of Virology 75, 1039-43.
92. Fruh, K., Simmen, K., Luukkonen, B. G. M., Bell, Y. C. & Ghazal, P. (2001). Virogenomics: a novel approach to antiviral drug discovery. Drug Discovery Today 6, 621-7.
93. van den Heuvel, S. & Harlow, E. (1993). Distinct roles for cyclin-dependent kinases in cell cycle control. Science 262, 2050-4.
94. Nikolic, M., Dudek, H., Kwon, Y. T., Ramos, Y. F. & Tsai, L. H. (1996). The cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation. Genes and Development 10, 816-25.
95. Chae, T., Kwon, Y. T., Bronson, R., Dikkes, P., Li, E. & Tsai, L. H. (1997). Mice lacking p35, a neuronal specific activator of Cdk5, display cortical lamination defects, seizures, and adult lethality. Neuron 18, 29-42.
96. Gilmore, E. C., Ohshima, T., Goffinet, A. M., Kulkarni, A. B. & Herrup, K. (1998). Cyclin-dependent kinase 5-deficient mice demonstrate novel developmental arrest in cerebral cortex. Journal of Neuroscience 18, 6370-7.
97. Kwon, Y. T., Tsai, L. H. & Crandall, J. E. (1999). Callosal axon guidance defects in p35(-/-) mice. Journal of Comparative Neurology 415, 218-29.
98. Fesquet, D., Morin, N., Doree, M. & Devault, A. (11997). Is Cdk7/cyclin H/MAT1 the genuine cdk activating kinase in cycling Xenopus egg extracts? Oncogene 15, 1303-7.
99. Larochelle, S., Pandur, J., Fisher, R. P., Salz, H. K. & Suter, B. (1998). Cdk7 is essential for mitosis and for in vivo Cdk-activating kinase activity. Genes and Development 12, 370-81.
100. Wu, L., Chen, P., Hwang, J. J., Barsky, L. W., Weinberg, K. I., Jong, A. et al. (1999). RNA antisense abrogation of MAT1 induces G1 phase arrest and triggers apoptosis in aortic smooth muscle cells. Journal of Biological Chemistry 274, 5564-72.
101. Pagano, M., Pepperkok, R., Lukas, J., Baldin, V., Ansorge, W., Bartek, J. et al. (1993). Regulation of the cell cycle by the cdk2 protein kinase in cultured human fibroblasts. Journal of Cell Biology 121, 101-11.
102. Pagano, M., Pepperkok, R., Verde, F., Ansorge, W. & Draetta, G. (1992). Cyclin A is required at two points in the human cell cycle. EMBO Journal 11, 961-71.
103. Schang, L. M. (2002). The cell cycle, cyclin-dependent kinases, and viral infections: new horizons and unexpected connections. In Progress in Cell Cycle Research, vol. 5 (Meijer, L., Jezequel, A. & Roberge, M., Eds). Plenum, London, UK (in press).
104. Schang, L. M. (2001). Cellular proteins (cyclin dependent kinases) as potential targets for antiviral drugs. Antiviral Chemistry and Chemotherapy 12, 157-78.
105. Carlson, B. A., Dubay, M. M., Sausville, E. A., Brizuela, L. & Worland, P. J. (1996). Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Research 56, 2973-8.
106. Gray, N., Detivaud, L., Doerig, C. & Meijer, L. (1999). ATP-site directed inhibitors of cyclin-dependent kinases. Current Medicinal Chemistry 6, 859-75.
107. Alessi, F., Quarta, S., Savio, M., Riva, F., Rossi, L., Stivala, L. A. et al. (1998). The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity. Experimental Cell Research 245, 8-18.
108. Alevizopoulos, K., Catarin, B., Vlach, J. & Amati, B. (1998). A novel function of adenovirus E1A is required to overcome growth arrest by the CDK2 inhibitor p27(Kip1). EMBO Journal 17, 5987-97.
109. Binarova, P., Dolezel, J., Draber, P., Heberle-Bors, E., Stmad, M. & Bogre, L. (1998). Treatment of Vicia laba root tip cells with specific inhibitors to cyclin-dependent kinases leads to abnormal spindle formation. Plant Journal 16, 697-707.
110. Choi, K. S., Eom, Y. W., Kang, Y., Ha, M. J., Rhee, H., Yoon, J. W. et al. (1999). Cdc2 and Cdk2 kinase activated by transforming growth factor-beta1 trigger apoptosis through the phosphorylation of retinoblastoma protein in FaO hepatoma cells. Journal of Biological Chemistry 274, 31775-83.
111. David-Pfeuty, T. (1999). Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells. Oncogene 18, 7409-22.
112. Frade, J. M. (2000). Unscheduled re-entry into the cell cycle induced by NGF precedes cell death in nascent retinal neurones. Journal of Cell Science 113, 1139-48.
113. Hsu, S. L., Yin, S. C., Liu, M. C., Reichert, U. & Ho, W. L. (1999). Involvement of cyclin-dependent kinase activities in CD437-induced apoptosis. Experimental Cell Research 252, 332-41.
114. Iseki, H., Ko, T. C., Xue, X. Y., Seapan, A., Hellmich, M. R. & Townsend, C. M., Jr (1997). Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells. Surgery 122, 187-94.
115. Iseki, H., Ko, T. C., Xue, X. Y., Seapan, A. & Townsend, C. M., Jr (1998). A novel strategy for inhibiting growth of human pancreatic cancer cells by blocking cyclin-dependent kinase activity. Journal of Gastrointestinal Surgery 2, 36-43.
116. Krucher, N. A., Meijer, L. & Roberts, M. H. (1997). The cyclin-dependent kinase (cdk) inhibitors, olomoucine and roscovitine, alter the expression of a molluscan circadian pacemaker. Cellular and Molecular Neurobiology 17, 495-507.
117. Krude, T. (2000). Initiation of human DNA replication in vitro using nuclei from cells arrested at an initiation-competent state. Journal of Biological Chemistry 275, 13699-707.
118. Lee, H. R., Chang, T. H., Tebalt, M. J., 3rd, Senderowicz, A. M. & Szabo, E. (1999). Induction of differentiation accompanies inhibition of Cdk2 in a non-small cell lung cancer cell line. International Journal of Oncology 15, 161-6.
119. Matsumoto, Y., Hayashi, K. & Nishida, E. (1999). Cyclin-dependent kinase 2 (Cdk2) is required for centrosome duplication in mammalian cells. Current Biology 9, 429-32.
120. Mermillod, P., Tomanek, M., Marchal, R. & Meijer, L. (2000). High developmental competence of cattle oocytes maintained at the germinal vesicle stage for 24 hours in culture by specific inhibition of MPF kinase activity. Molecular Reproduction and Development 55, 89-95.
121. Mgbonyebi, O. P., Russo, J. & Russo, I. H. (1998). Roscovitine inhibits the proliferative activity of immortal and neoplastic human breast epithelial cells. Anticancer Research 18, 751-5.
122. Padmanabhan, J., Park, D. S., Greene, L. A. & Shelanski, M. L. (1999). Role of cell cycle regulatory proteins in cerebellar granule neuron apoptosis. Journal of Neuroscience 19, 8747-56.
123. Patrick, G. N., Zhou, P., Kwon, Y. T., Howley, P. M. & Tsai, L. H. (1998). p35, the neuronal-specif ic activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway. Journal of Biological Chemistry 273, 24057-64.
124. Planchais, S., Glab, N., Trehin, C., Perennes, C., Bureau, J. M., Meijer, L. et al. (1997). Roscovitine, a novel cyclin-dependent kinase inhibitor, characterizes restriction point and G2/M transition in tobacco BY-2 cell suspension. Plant Journal 12, 191-202.
125. Rousseau, A. & Vilain, J. P. (2000). Differential effects of 6-DMAP, olomoucine and roscovitine on Xenopus oocytes and eggs. Zygote 8, 3-14.
126. Sankrithi, N. &Eskin, A. (1999). Effects of cyclin-dependent kinase inhibitors on transcription and ocular circadian rhythm of Aplysia. Journal of Neurochemistry 72, 605-13.
127. Schutte, B., Nieland, L., van Engeland, M., Henfling, M. E., Meijer, L. & Ramaekers, F. C. (1997). The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics. Experimental Cell Research 236, 4-15.
128. Yakisich, J. S., Boethius, J., Lindblom, I. O., Wallstedt, L., Vargas, V. I., Siden, A. et al. (1999). Inhibition of DNA synthesis in human gliomas by roscovitine. Neuroreport 10, 2563-7.
129. Yakisich, J. S., Siden, A., Idoyaga Vargas, V., Eneroth, P. & Cruz, M. (1998). Early inhibition of DNA synthesis in the developing rat cerebral cortex by the purine analogues olomoucine and roscovitine. Biochemical and Biophysical Research Communications 243, 674-7.
130. Abraham, R. T., Acquarone, M., Andersen, A., Asensi, A., Belle, R., Berger, F. et al. (1995). Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. Biology of the Cell 83, 105-20.
131. Buquet-Fagot, C., Lallemand, F., Montagne, M. N. & Mester, J. (1997). Effects of olomoucine, a selective inhibitor of cyclin-dependent kinases, on cell cycle progression in human cancer cell lines. Anti-Cancer Drugs 8, 623-31.
132. Corellou, F., Bisgrove, S. R., Kropf, D. L., Meijer, L., Kloareg, B. & Bouget, F. Y. (2000). A S/M DNA replication checkpoint prevents nuclear and cytoplasmic events of cell division including centrosomal axis alignment and inhibits activation of cyclin-dependent kinase-like proteins in fucoid zygotes. Development 127, 1651-60.
133. Glab, N., Labidi, B., Qin, L. X., Trehin, C., Bergounioux, C. & Meijer, L. (1994). Olomoucine, an inhibitor of the cdc2/cdk2 kinases activity, blocks plant cells at the G1 to S and G2 to M cell cycle transitions. FEBS Letters 353, 207-11.
134. Huang, D., Farkas, I. & Roach, P. J. (1996). Pho85p, a cyclin-dependent protein kinase, and the Snf1p protein kinase act antagonistically to control glycogen accumulation in Saccharomyces cerevisiae. Molecular and Cellular Biology 16, 4357-65.
135. Kwon, Y. G., Lee, S. Y., Choi, Y., Greengard, P. & Nairn, A. C. (1997). Cell cycle-dependent phosphorylation of mammalian protein phosphatase 1 by cdc2 kinase. Proceedings of the National Academy of Sciences, USA 94, 2168-73.
136. Malecz, N., Foisner, R., Stadler, C. & Wiche, G. (1996). Identification of plectin as a substrate of p34cdc2 kinase and mapping of a single phosphorylation site. Journal of Biological Chemistry 271, 8203-8.
137. Park, D. S., Farinelli, S. E. & Greene, L. A. (1996). Inhibitors of cyclin-dependent kinases promote survival of post-mitotic neuronally differentiated PC12 cells and sympathetic neurons. Journal of Biological Chemistry 271, 8161-9.
138. Park, D. S., Morris, E. J., Greene, L. A. & Geller, H. M. (1997). G1/S cell cycle blockers; and inhibitors of cyclin-dependent kinases suppress camptothecin-induced neuronal apoptosis. Journal of Neuroscience 17, 1256-70.
139. Paulson, J. R., Patzlaff, J. S. & Vallis, A. J. (1996). Evidence that the endogenous histone H1 phosphatase in HeLa mitotic chromosomes is protein phosphatase 1, not protein phosphatase 2A. Journal of Cell Science 109, 1437-47.
140. Veeranna, Shetty, K. T., Amin, N., Grant, P., Albers, R. W. & Pant, H. C. (1996). Inhibition of neuronal cyclin-dependent kinase-5 by staurosporine and purine analogs is independent of activation by Munc-1 8. Neurochemical Research 21, 629-36.
141. Kaur, G., Stetler-Stevenson, M., Sebers, S., Worland, P., Sedlacek, H., Myers, C. et al. (1992). Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. Journal of the National Cancer Institute 84, 1736-40.
142. Losiewicz, M. D., Carlson, B. A., Kaur, G., Sausville, E. A. & Worland, P. J. (1994). Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochemical and Biophysical Research Communications 201, 589-95.
143. Chang, Y. T., Gray, N. S., Rosania, G. R., Sutherlin, D. P., Kwon, S., Norman, T. C. et al. (1999). Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chemistry and Biology 6, 361-75.
144. Schnier, J. B., Kaur, G., Kaiser, A., Stinson, S. F., Sausville, E. A., Gardner, J. et al. (1999). Identification of cytosolic aldehyde dehydrogenase 1 from non-small cell lung carcinomas as a flavopiridol-binding protein. FEBS Letters 454, 100-4.
145. Marko, D., Schatzle, S., Friedel, A., Genzlinger, A., Zankl, H., Meijer, L. et al. (2001). Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells. British Journal of Cancer 84, 283-9.